Cat. No. 2861
Alternative Name: Dexanabinol
Chemical Name: (6aS,10aS)-3-(1,1-Dimethylheptyl)-6
Biological ActivityNMDA antagonist (IC50 = 11 μM for inhibition of [3H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC50 = 3.8 μM) and enhances dopamine D1 receptor activity. Inhibits NF-κB, reducing TNF-α, IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Eshhar et al (1993) HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5 237. PMID: 8298080.
Gallily et al (1997) Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J.Pharmacol.Exp.Ther. 283 918. PMID: 9353414.
Striem et al (1997) Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. Eur.J.Pharmacol. 338 205. PMID: 9424014.
Juttler et al (2004) The cannabinoid dexanabinol is an inhibitor of the nuclear factor kappa B (NF-κB). Neuropharmacology 47 580. PMID: 15380375.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: HU 211, supplier, NF-κB, NF-kappaB, NF-kB, inhibitors, decreases, TNF-α, TNF-alpha, IL-6, NO, production, NMDA, antagonists, receptors, Nuclear, Factor, Kappa, B, Cytokine, Signaling, Signalling, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, HU211, NMDA Receptor Antagonists
Find multiple products by catalog number
New Products in this Area
Potent and noncompetitive NMDA receptor antagonist
One Day Symposium
January 12, 2016